RxDoctor Payments Data

Gilbert Kuhn, MD

Pulmonary Disease · Santa Monica, CANPI 1144317629

Payments from drug & device makers

$2,792in general payments, 2019–2025

Across 134 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$426
  • Amgen$297
  • E.r. Squibb & Sons, L.L.C.$225
  • Mylan Specialty L.p.$169
  • Boehringer Ingelheim$162
  • plus $511 from 14 others

What the payments were for

  • Food & beverage$2,780100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,792 in reported general payments places this provider in the 55th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$330,217
Medicare patients
852
Services billed
4,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter259$206,039
Breo ElliptaFluticasone/Vilanterol63$36,125
Spiriva HandihalerTiotropium Bromide42$23,212
Stiolto RespimatTiotropium Br/Olodaterol Hcl26$16,348
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$15,399
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$12,678
EliquisApixaban12$6,845
Wixela InhubFluticasone Propion/Salmeterol26$3,254
SymbicortBudesonide/Formoterol Fumarate13$3,249
Azelastine-FluticasoneAzelastine/Fluticasone22$2,739
Albuterol Sulfate HfaAlbuterol Sulfate86$2,691
Levalbuterol Tartrate HfaLevalbuterol Tartrate12$1,348
Ventolin HfaAlbuterol Sulfate20$1,129
Azelastine Hcl21$994
Methylprednisolone103$967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,003$254,843344 claims
AstraZenecaBreztri Aerosphere, Symbicort$426$18,64927 claims
Boehringer IngelheimStiolto Respimat$162$16,34826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →